Antibe Therapeutics Inc. (TSE:ATE – Get Rating) Senior Officer Scott Wilson Curtis bought 20,000 shares of the stock in a transaction on Friday, July 8th. The stock was purchased at an average cost of C$0.62 per share, with a total value of C$12,400.00. Following the completion of the purchase, the insider now directly owns 80,000 shares in the company, valued at approximately C$49,600.
ATE stock opened at C$0.60 on Thursday. The stock has a market capitalization of C$30.83 million and a P/E ratio of -1.12. The company has a debt-to-equity ratio of 0.29, a quick ratio of 11.92 and a current ratio of 13.07. Antibe Therapeutics Inc. has a one year low of C$0.59 and a one year high of C$3.65. The company has a 50 day moving average price of C$0.66 and a two-hundred day moving average price of C$0.70.
Get Antibe Therapeutics alerts:About Antibe Therapeutics (Get Rating)
Antibe Therapeutics Inc, a biotechnology company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs.Recommended Stories
- 3 More Stocks For the Second Half to Consider
- United Natural Foods Stock is Ready to be Snacked On
- Elastic Stock is a Buoyant Search Play
- 3M (NYSE: MMM) Is Now A Good Time To Buy 3M After Downgrades?
- Apple's Global Smartphone Market Share Increases by 20%, Should You Consider The Stock?
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.